New hemophilia drug Inno8 passes first safety check in healthy men
NCT ID NCT06649630
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tested the safety of a new medicine, Inno8, in 95 healthy men aged 18-45. Participants received either Inno8 or a placebo by injection or as tablets. The goal was to check for side effects and how the drug moves through the body, which will help plan future studies in people with hemophilia A.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.